title: Significance of human beta-defensins in the epithelial lining fluid of patients with chronic lower respiratory tract infections.
abstract: Human beta-defensins (hBDs) are the most abundant antimicrobial peptides in epithelial cells, and function in the host immune system. Respiratory epithelial cells express hBDs to inhibit bacterial proliferation during respiratory tract infections. The aim of this study was to investigate the release of hBDs into the respiratory tract and their benefit as a host defence system in chronic Pseudomonas aeruginosa infections. The levels of four hBD peptides (hBD-1-hBD-4) were measured in the bronchial epithelial lining fluid (ELF) of nine patients with chronic lower respiratory tract infection caused by P. aeruginosa. Eight patients with idiopathic pulmonary fibrosis and eight volunteers free of pulmonary disease were recruited as controls. ELF was obtained by bronchoscopic microsampling and hBD levels were measured by radioimmunoassays. The antimicrobial effects of hBDs were studied individually and in combination using an in-vitro colony count assay for P. aeruginosa. Concentrations of hBD-1 and hBD-3 tended to be higher in patients with chronic lower respiratory tract infection than in the controls. hBD-2 and hBD-4 were detected in ELF from five and four of nine patients, respectively, but the hBD levels in controls were all below the limits of detection. All patients with infection caused by mucoid P. aeruginosa had detectable hBD-2 and hBD-4 levels in ELF. In-vitro colony count assays showed a potential synergism between hBD-2 and hBD-4 in inhibiting bacterial proliferation. The findings indicate that hBDs, especially hBD-2 and hBD-4, are pathophysiologically important in infections caused by mucoid strains of P. aeruginosa.
authors.affiliation: Third Department of Internal Medicine, Miyazaki University School of Medicine, Miyazaki, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Yanagi
authors.forename: J
authors.initials: J
authors.lastname: Ashitani
authors.forename: K
authors.initials: K
authors.lastname: Imai
authors.forename: Y
authors.initials: Y
authors.lastname: Kyoraku
authors.forename: A
authors.initials: A
authors.lastname: Sano
authors.forename: N
authors.initials: N
authors.lastname: Matsumoto
authors.forename: M
authors.initials: M
authors.lastname: Nakazato
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000032:analysis / Q000378:metabolism* / Q000494:pharmacology*; D001999:Bronchoscopy; D002908:Chronic Disease; D015169:Colony Count, Microbial; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D011863:Radioimmunoassay; D020545:Respiratory Mucosa / Q000378:metabolism* / Q000473:pathology; D012141:Respiratory Tract Infections / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D023083:beta-Defensins / Q000032:analysis / Q000378:metabolism* / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D023083:beta-Defensins